Nicholas J. Naclerio, Ph.D., is the Founding Partner of Illumina Ventures. See sector focus and contact routes.
Nicholas J. Naclerio, Ph.D., is the Founding Partner of Illumina Ventures, an early-stage venture capital firm based in San Francisco that focuses exclusively on genomics and precision health. His investment thesis targets early-stage companies at the intersection of technology and human health, with sectors including life science tools, clinical diagnostics, therapeutics, and digital health. The firm typically invests in early-stage ventures, though specific check sizes and whether Naclerio leads or follows are not publicly detailed in available sources. Notable portfolio companies include Alamar Biosciences, DNA Script, Encoded Therapeutics, and Pattern Bioscience, all of which are listed on Illumina Ventures’ website. Naclerio brings deep operational background from his prior role as SVP of Corporate & Venture Development at Illumina Inc., where he led ten acquisitions and over a dozen venture investments, including forming Helix and GRAIL. He does not appear to have published distinctive public writing or a unique point of view beyond his stated passion for building companies that merge technology with human health.
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in San Francisco.
Investors like Nicholas J. Naclerio · Full investor directory · Investor access · Company funding database